Welcome to our dedicated page for Denali Therapeut news (Ticker: DNLI), a resource for investors and traders seeking the latest updates and insights on Denali Therapeut stock.
Denali Therapeutics Inc. (NASDAQ: DNLI) is a biotechnology and biopharmaceutical company developing product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases, lysosomal storage diseases and other serious conditions. This news page aggregates company-reported updates, press releases and related market announcements about Denali’s programs and corporate activities.
Readers can find coverage of Denali’s investigational enzyme replacement therapy tividenofusp alfa (DNL310) for Hunter syndrome (MPS II), including milestones related to its Biologics License Application, Priority Review status and the ongoing Phase 2/3 COMPASS study. News items also describe clinical and regulatory progress for other TransportVehicle™-enabled programs such as DNL126 (ETV:SGSH) for Sanfilippo syndrome type A, DNL952 (ETV:GAA) for Pompe disease, and TV-enabled antibody and oligonucleotide programs for Alzheimer’s and Parkinson’s disease.
In addition to pipeline updates, Denali’s releases discuss collaborations with partners such as Biogen, Takeda and Sanofi, a royalty funding agreement with Royalty Pharma tied to future net sales of tividenofusp alfa, and financial results reflecting research and development spending and launch preparations. Corporate governance and leadership changes, board appointments and participation in healthcare and investor conferences are also reported.
Investors and followers of DNLI can use this page to review historical and recent announcements on clinical trial progress, regulatory interactions, financing transactions and strategic partnerships as disclosed by the company in its public communications.
Denali Therapeutics Inc. (NASDAQ: DNLI) has signed definitive collaboration and license agreements with Biogen, receiving $560 million upfront. Biogen also invested $465 million in Denali through a share purchase. Both companies will co-develop LRRK2 inhibitors for Parkinson’s disease, sharing development costs and profits. Denali could earn up to $1.125 billion in milestone payments. Additionally, Biogen has exclusive option rights on future programs using Denali’s blood-brain barrier technology. Clinical trials for Denali's LRRK2 inhibitor, DNL151, are set to begin in 2021.
Denali Therapeutics (NASDAQ: DNLI) will host a webinar on October 15 from 1:00 to 4:00 p.m. Eastern Time, focusing on its innovative blood-brain barrier (BBB) transport technology. This webinar aims to provide insights into the company’s therapeutics portfolio, including ETV:IDS (DNL310) for Hunter syndrome, currently in a Phase 1/2 study. The TV platform technology enhances brain exposure of therapeutics, demonstrating significant efficacy in animal models. Registration for the live event is available on Denali's investor page, with a replay offered afterwards.
Denali Therapeutics (NASDAQ: DNLI) reported its second-quarter 2020 financial results, showcasing strong progress in its pipeline despite COVID-19 challenges. The company entered a collaboration with Biogen for Parkinson's LRRK2 program, receiving $560 million upfront and a $465 million equity investment. Denali's DNL151 is advancing into late-stage studies, and DNL310 is in Phase 1/2 for Hunter syndrome. Financially, it recorded a net loss of $58.8 million with $5.8 million in collaboration revenue. The cash position stands at $556.8 million as of June 30, 2020.
Denali Therapeutics (NASDAQ: DNLI) announced that DNL151 will advance into late-stage studies for Parkinson's disease treatment in patients with kinase activating mutations in LRRK2 and sporadic cases. The company, in collaboration with Biogen, will finalize clinical development plans with patient enrollment expected to start in 2021. DNL151 has shown an acceptable safety profile and achieved target engagement in earlier phases. The ongoing Phase 1 studies have included 162 healthy volunteers and 25 Parkinson's patients, indicating promising potential for treating neurodegenerative diseases.
Denali Therapeutics (NASDAQ: DNLI) has announced the commencement of dosing for DNL758 (SAR443122) in a Phase 1b trial aimed at assessing its safety and efficacy in patients with severe COVID-19. Partnered with Sanofi, DNL758 is a small molecule inhibitor of RIPK1, designed to mitigate the immune response to SARS-CoV-2. The trial seeks to reduce tissue damage from inflammation, potentially improving recovery rates. Sanofi oversees the trial's development and financing, while Denali will receive milestone payments and royalties from product sales.
Denali Therapeutics (NASDAQ: DNLI) and Sanofi have decided to pause clinical activities for DNL747 due to the totality of data suggesting a superior profile for the backup compound DNL788. The companies plan to accelerate DNL788’s development for neurological indications, aiming to initiate clinical testing by early 2021. While DNL747 demonstrated safety in Phase 1b studies for ALS and Alzheimer’s, it faced limitations on dose escalation due to toxicity findings. Additionally, Sanofi is planning further studies for its compound DNL758 after a successful Phase 1 trial.
Denali Therapeutics (NASDAQ: DNLI) has announced advancements in its proprietary Transport Vehicle (TV) technology, enabling effective delivery of therapeutic proteins across the blood-brain barrier (BBB). Two significant papers published in Science Translational Medicine detail the TV platform's ability to improve brain exposure of therapeutic proteins, specifically in relation to DNL310, aimed at treating Hunter syndrome. Clinical data for DNL310 is expected by late 2020, and the EngageHunter.com website offers information on ongoing studies and patient engagement.
Denali Therapeutics Inc. (NASDAQ: DNLI) reported a net loss of $56.8 million for Q1 2020, compared to $39.0 million in the same quarter last year. Collaboration revenue decreased to $3.6 million, attributed mainly to a $2.9 million decline from Sanofi, offset by a $2.3 million increase from Takeda. Total R&D expenses rose to $51.0 million, influenced by external expenses for key programs and higher personnel costs. General and administrative expenses also increased to $12.6 million. As of March 31, 2020, the company held $596.9 million in cash and marketable securities.